LeRomancer&Trédan Lab

Endocrine resistance, Protein Methylation and Breast Cancer

[LifeScienceAlliance @LSAjournal]

In triple-negative breast cancer, PRMT5 functions as a master transcriptional coregulator of the glucocorticoid receptor regulating cell migration after dexamethasone treatment. PRMT5 acts in this case as a scaffolding protein independently of its catalytic activity to promote HP1g recruitment @PoulardCoralie @CRCL
https://t.co/7J0hLYInY7

[Mammary Cell News @MammaryCell]

There is currently no predictive marker of response to #tamoxifen, to guide treatment decisions for ERα+ #BreastCancer.

Dr. Muriel Romancer's team identified 🔎 nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen.

https://t.co/G1UtsgNkEV

[LeRomancer&Trédan Lab @LeRomancerLab]

AVANCÉE DANS LA RECHERCHE DU CANCER DU SEIN https://t.co/WZZygBBjz1 via @BFMLyon

[Cancer Research Center of Lyon @crcl]

Latest study from M Le Romancer & O Trédan Lab @crcl. Great work with potential clinical application!
👏👏 #breastcancer #research

[LeRomancer&Trédan Lab @LeRomancerLab]

Toute l'équipe réunie pour La Scintillante, la course pour la recherche du Centre Léon Bérard! @CLCCLeonBerard @crcl